Trial
NCT04142554
Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
UNC Lineberger Comprehensive Cancer Center
Collaborators
Incyte Corporation
Condition
Breast Cancer
Intervention
Parsaclisib
Why stopped
Funding withdrawn from funding source.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-11-03